V116 Well-Tolerated With Broad Immune Responses in Pneumococcal Vaccine-Naïve Older Adults
Pharmacy Times
AUGUST 12, 2025
The vaccine showed superior immune response for unique serotypes compared to PPSV23, with higher OPA titers. SHOW MORE In a phase 3 trial, V116 demonstrated significant immunogenicity in older adults who had not before received a pneumococcal vaccination. 1 Older adults are at increased risk of invasive pneumococcal disease.
Let's personalize your content